Kineta Acquired by TuHura Biosciences | Healthcare M&A Deal

TuHura Biosciences has completed the acquisition of Kineta, a medical devices business in Florida, for $34,621,304. TuHura Biosciences acquisitions expand healthcare M&A capabilities by adding Kineta’s KVA12123 antibody program, renamed TBS-2025, to its pipeline. Kineta acquisition supports TuHura’s public company acquisition strategy in FL acquisitions and strengthens its platform in medical devices and healthcare deals FL. The merger acquisition closed on June 30, 2025, using a two-step merger structure, with TuHura Biosciences acquiring Kineta through wholly owned Delaware merger subsidiaries under U.S. GAAP acquisition accounting.